Navigating the Small-Cap Landscape: A Q2 2025 Review
Understanding the Fund's Performance in Q2 2025
During the second quarter of 2025, the Aberdeen U.S. Small Cap Equity Fund reported a positive return, measured on a gross-of-fees basis. However, its performance did not quite match that of its benchmark, the Russell 2000 Index. This period saw U.S. small-cap equities generally trending upwards, yet their overall returns were somewhat subdued when compared to the broader U.S. equity market. A notable factor impacting the fund's results was the decline in the shares of Corcept Therapeutics, primarily attributed to a downturn in the company’s product sales, which adversely affected the fund's overall performance.